We be lieve that the ar ti cle by Dal fen and Stewart pub lished in April 2001 (1) fails to an swer the ques tion that the ti tle proposes and may mis lead cli ni cians. The ob jec tives set forth by the authors were to de ter mine risk fac tors that would alert phy si cians to the in creased pos si bil ity of se vere ad verse drug re ac tions (ADRs) or death in pa tients on se lec tive se ro tonin re up take in hibi tor (SSRI) ther apy. The meth od ol ogy for the study was flawed from the be gin ning, with the data com ing from Health Cana da's da ta base of Adverse Drug Re port ing. Pa tients and physi cians alike can re port any thing they deem an ADR to this da ta base. In deed, the ar ti cle it self ad dresses this short coming and states that this source is of "question able data qual ity and re li abil ity."The most trou bling as pect of this ar ti cle, however, is that it at tempts to link the in gestion of SSRIs to the fa tal over doses. Yet, due to its ret ro spec tive na ture, it is im possi ble to re port cau sa tion be tween the SSRI and the bad out comes. Next, the arti cle states that the mean number of drugs taken when death re sulted or when se vere ADRs oc curred was 3 and 2, re spec tively. The co in gested drugs most com monly en coun tered in cluded aceta mino phen, lith ium, cal cium chan nel block ers, and tri cyc lic an ti de pres sants. The ar ti cle com pletely ig nores the sig nifi cant morbid ity and mor tal ity as so ci ated with these other medi ca tions or the pos si bil ity that these drugs are the pri mary cause of the ADR The authors then list sev eral clini cal impli ca tions of this re search, such as the need for phy si cians to pay at ten tion to past his tory of in ten tional over dose and to in form pa tients of spe cific side ef fects and the pos si ble dan gers of com bin ing SSRIs with other CYP-P450-me tabolized drugs. While no one would ar gue that these im pli ca tions are es sen tial to the prac tice of pre scrib ing SSRI ther apy, they are also ap pli ca ble to com mon prescrib ing prac tice for all medi ca tions and need not be based on the con clu sions of this pa per.
Dear Edi tor:
We be lieve that the ar ti cle by Dal fen and Stewart pub lished in April 2001 (1) fails to an swer the ques tion that the ti tle proposes and may mis lead cli ni cians. The ob jec tives set forth by the authors were to de ter mine risk fac tors that would alert phy si cians to the in creased pos si bil ity of se vere ad verse drug re ac tions (ADRs) or death in pa tients on se lec tive se ro tonin re up take in hibi tor (SSRI) ther apy. The meth od ol ogy for the study was flawed from the be gin ning, with the data com ing from Health Cana da's da ta base of Adverse Drug Re port ing. Pa tients and physi cians alike can re port any thing they deem an ADR to this da ta base. In deed, the ar ti cle it self ad dresses this short coming and states that this source is of "question able data qual ity and re li abil ity."The most trou bling as pect of this ar ti cle, however, is that it at tempts to link the in gestion of SSRIs to the fa tal over doses. Yet, due to its ret ro spec tive na ture, it is im possi ble to re port cau sa tion be tween the SSRI and the bad out comes. Next, the arti cle states that the mean number of drugs taken when death re sulted or when se vere ADRs oc curred was 3 and 2, re spec tively. The co in gested drugs most com monly en coun tered in cluded aceta mino phen, lith ium, cal cium chan nel block ers, and tri cyc lic an ti de pres sants. The ar ti cle com pletely ig nores the sig nifi cant morbid ity and mor tal ity as so ci ated with these other medi ca tions or the pos si bil ity that these drugs are the pri mary cause of the ADR The authors then list sev eral clini cal impli ca tions of this re search, such as the need for phy si cians to pay at ten tion to past his tory of in ten tional over dose and to in form pa tients of spe cific side ef fects and the pos si ble dan gers of com bin ing SSRIs with other CYP-P450-me tabolized drugs. While no one would ar gue that these im pli ca tions are es sen tial to the prac tice of pre scrib ing SSRI ther apy, they are also ap pli ca ble to com mon prescrib ing prac tice for all medi ca tions and need not be based on the con clu sions of this pa per.
This ar ti cle can eas ily be re ti tled "Patients with Ad verse Drug Re ac tions Who Hap pen to be on SSRIs." The data and con clu sions are very mis lead ing to cli nicians and should not in flu ence the cur rent prac tice of any phy si cian pre scrib ing SSRIs. 
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The Authors Reply
Dear Edi tor:
Drug regu la tors, manu fac tur ers and physi cians alike rec og nize the trou bling dispar ity be tween rela tively rig or ous re quire ments for li cens ing of thera peu tic drugs, com pared with their hap haz ard post mar ket ing sur veil lance. This is es pecially trou bling when one con sid ers the strict but rela tively ar ti fi cial con di tions un der which clini cal tri als for li cens ing are con ducted. Pa tients are care fully selected and rela tively re li able, with out signifi cant comor bid ity, and not tak ing con comi tant medi ca tions. Moreo ver, they are care fully and regu larly monitored by study per son nel ex ten sively briefed about the spe cific drug. How differ ent this is from the con di tions un der which these drugs are pre scribed clini cally! Post mar ket ing sur veil lance chiefly re lies on vol un tary re ports to ad verse drug re action (ADR) da ta bases, pub lished clini cal case re ports, and oc ca sional re views of ad min is tra tive da ta bases. None of these meth ods are very re li able, but they are the best drug in tel li gence we cur rently have. Should we stop ADR re port ing, not analyze ADR re ports, not pub lish case reports of ad verse drug out comes, and stop re search ing in com plete ad min is tra tive da ta bases in our at tempts to dis cover how drugs per form in the real world of clini cal prac tice? Al though im per fect, such studies have in the past led to the dis cov ery of the dan gers of tha lido mide, di eth yl stil bestrol, and a host of other drugs. Surely it is pref er able to col lect, ana lyze, and re port on the avail able drug da ta bases, not ing the ca ve ats and cau tions as we have done, while si mul ta ne ously look ing for bet ter ways to moni tor drugs af ter li cens ing. This is in keep ing with the strate gies of sev eral coun tries and re port ing agen cies, in clud ing Health Can ada, which regularly pub lishes up dates on ADRs in the Ca na dian Medi cal As so cia tion Jour nal.
Dr Shaps, Dr Tri ge nis, and Dr Bar ru eto fear that our ar ti cle is "mis lead ing to clini cians," but they ap pear to have ig nored our ex ten sive ex plicit ca ve ats about the limi ta tions of the Ca na dian Ad verse Drug Re ac tion Re port ing Da ta base (see the first 2 para graphs of the Dis cus sion [p 260]). Moreo ver, in com plain ing that "the ar ti cle com pletely ig nores the signifi cant mor bid ity and mor tal ity as so ciated with these other medi ca tions or the pos si bil ity that these drugs are the primary cause of the ADR," they ap par ently also missed the last 2 para graphs of the Dis cus sion (p 261), in which we point out the many other drugs as so ci ated with Tor sades de Poin tes (TP) and the pos sibil ity that the car dio vas cu lar and other ad verse drug ef fects may not be a di rect 
